Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189176
Status:
COMPLETED
Last Update Posted:
2013-02-06
First Post:
2005-09-10
Brief Title:
Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
Sponsor:
University of Michigan
Organization:
University of Michigan
Study Overview
Official Title:
Phase III Trial of Tetrathiomolybdate TM in Patients With Usual Interstitial Pneumonia Refractory to Previous Therapy
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety of the administration of a copper chelating agent tetrathiomolybdate for patients with idiopathic pulmonary fibrosis that have failed previous treatment The primary endpoint for this study is safety with secondary endpoints including change in pulmonary function exercise capacity and quality of life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None